Home

JEFFREY D CAPELLO

CIK 1224108 · EVP & Chief Financial Officer · last filed 2026-06-23

JEFFREY D CAPELLO is an EVP & Chief Financial Officer who has filed 66 SEC Form 4 insider transactions across 7 companies since 2007. The most recent filing, for AGIO, was dated Jun 23, 2026. Across all open-market trades the lifetime net is −$13.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.4M across reported positions. 22 SEC filings were submitted jointly with BOSTON SCIENTIFIC CORP.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.44M

Companies

7

Total Filings

66

Lifetime Open-Market Net

-$13.49M

Filer Profile

Reported Address
C/O NEOGEN CORP.
620 LESHER PLACE
LANSING, MI 48912
Related Filers
BOSTON SCIENTIFIC CORP — 22 joint filings, latest 2013-12-02
BIOGEN INC. — 6 joint filings, latest 2020-02-14
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
AGIO Director 10,865 $33.60 $365.1K $0 7 2026-06-23
NEOG Director 32,502 $11.78 $382.9K $100.2K 10 2025-10-29
BIIB EVP & Chief Financial Officer 3,118 $217.15 $677.1K $0 5 2020-02-14
Tempest Therapeutics, Inc. (OVAS) Delisted Director — — — $0 5 2018-07-06
Salarius Pharmaceuticals, Inc. (FLKS) Delisted Director — — — $0 3 2017-07-27
BSX EVP & Chief Financial Officer 447 $42.98 $19.2K -$12.60M 30 2013-12-02
REVVITY, INC. (PKI) Delisted SVP & CFO 91,428 $115.24 $10.54M -$989.9K 4 2008-01-31

Recent Filings

66 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-23 AGIO Mixed +2,816 $0 EDGAR
2026-06-16 AGIO Exer (M) +1,976 $0 EDGAR
2025-10-29 NEOG Exer (M) +1,777 $11.0K EDGAR
2025-10-28 NEOG Exer (M) +2,025 $12.5K EDGAR
2025-10-27 NEOG Grant (A) +19,769 $120.0K EDGAR
2025-10-09 NEOG Exer (M) +2,071 $11.7K EDGAR
2025-06-23 AGIO Mixed +2,120 $0 EDGAR
2025-06-17 AGIO Exer (M) +1,977 $0 EDGAR
2025-04-22 NEOG Buy (P) +20,712 $100.2K EDGAR
2024-10-29 NEOG Exer (M) +1,776 $24.5K EDGAR
Showing 1–10 of 66
Page 1 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.